COMP <GO>
RLMD vs EBS // EV/EBITDA & P/E VALUATION
Relmada Therapeutics Inc. (NASDAQ) VS. Emergent BioSolutions Inc. (NYSE) • 15-METRIC TALLY: RLMD 0
— EBS 4
■ METRIC PARITY
LAST: $3.44 (+2.69%) • MKT CAP: $366.9M
valuation
—
LAST: $7.22 (+1.83%) • MKT CAP: $370.2M
valuation
6.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. EBS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RLMD | EBS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 56.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 8.90% | -43.90 | EBS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 6.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.48% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 13.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 7.10% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -28.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.41 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 8/9 | -7.00 | EBS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 53.0 | -0.08 | EBS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 6.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $366.9M | $370.2M | -$3.2M | EBS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RLMD REV | EBS REV | RLMD GROSS % | EBS GROSS % | RLMD FCF | EBS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $742.9M | — | 56.1% | -$45.8M | $156.8M |
| FY 2024 | $0 | $1.04B | — | 34.7% | -$51.8M | $35.8M |
| FY 2023 | — | $1.05B | — | — | — | -$206.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
EBS // BETA —